Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use

Abstract

Our experience indicates that everolimus may be of value in selected patients with therapy-resistant AIH and comorbidity/side effects that excludes the use of CNIs.